Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

CHRONIC MYELOGENOUS LEUKEMIA

External validation of the predictive scoring systems for molecular responses in chronic myeloid leukaemia receiving initial imatinib-therapy

Leukemia volume 37, pages 1922–1924 (2023)Cite this article

Subjects

Definitions of diagnosis and monitoring of CML followed European LeukemiaNet recommendations [2,3,4]. e14a2 and/or e13a2 BCR::ABL1 transcript levels were analysed by quantitative real-time polymerase chain reaction (qRT‒PCR) with an ABL control and converted to international scales (BCR::ABL1IS) using laboratory-specific conversion factors when the value was <10%. Stable molecular responses were defined as by ≥2 concordant consecutive tests. Last follow-up was December, 2022.

Subjects co-variates were shown in Supplementary Table 1. Median follow-up is 51 months (Interquartile range [IQR], 28–84 months). In total, 2184 and 2137 subjects were evaluable for MMR and MR4. In total, 1407 subjects (64%) achieved a MMR and 924 (43%), a stable MR4. Seven-year cumulative incidences of MMR and MR4 were 70% (95% confidence interval [CI], 68, 72%) and 55% (52, 57%).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Cumulative incidences of MMR and MR4 by the predictive scoring systems.
Fig. 2: Concordance analyses of the predictive scoring systems for MMR and MR4.

Data availability

Data are available from the corresponding author upon reasonable request.

References

  1. Zhang XS, Gale RP, Li ZY, Zhang MY, Huang XJ, Jiang Q. Predictive scoring systems for molecular responses in persons with chronic phase chronic myeloid leukemia receiving initial imatinib therapy. Leukemia. 2022;36:2042–9.

    Article  CAS  PubMed  Google Scholar 

  2. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809–20.

    Article  CAS  PubMed  Google Scholar 

  3. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Adams ST, Leveson SH. Clinical prediction rules. BMJ. 2012;344:d8312.

    Article  PubMed  Google Scholar 

  6. Van Calster B, Wynants L, Verbeek JFM, Verbakel JY, Christodoulou E, Vickers AJ, et al. Reporting and interpreting decision curve analysis: a guide for investigators. Eur Urol. 2018;74:796–804.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Steyerberg EW. Coding of Categorical and Continuous Predictors. In: Steyerberg EW (ed). Clinical Prediction Models: A Practical Approach to Development, Validation, and Updating. Cham: Springer International Publishing; 2019, pp 175–90.

  8. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29–36.

    Article  CAS  PubMed  Google Scholar 

  9. Kamarudin AN, Cox T, Kolamunnage-Dona R. Time-dependent ROC curve analysis in medical research: current methods and applications. BMC Med Res Methodol. 2017;17:53.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank the following medical staffs who provided patients data: Yanli Zhang, Xin Du, Jianyu Weng, Weiming Li, Na Xu, Xiaoli Liu, Chunyan Chen, Hai Lin, Guohui Li, Rong Liang, Zhuogang Liu, Xiaodong Wang, Yanqing Zhang, Yanqiu Han, Chunshui Liu, Jianda Hu, Lie Lin, Wei Yang, Zhenfang Liu, Li Meng, Chuanqing Tu, Caifeng Zhen, Zeping Zhou, Yanliang Bai, Huiying Qiu, Suning Chen, Fei Li, Jianxin Guo, Zelin Liu, Hui Sun, Li Zhou, Ru Feng, Xiuli Sun, Xiaohui Suo, Weihua Zhang, Yuanjun Zheng, Lijie Yang, Zhiqiang Sun, Rongxia Wei, Jijun Wang, Lan Ma, Qingshu Zeng, Zhen Xiao, Junxia Meng, Xiaonan Zhang, Hebing Zhou, Congmeng Lin, Pengliang Xin, Yanping Ma, Xiaoyan Ge, Yujuan Yang, Yu Jing, Lijun Wang, Huanling Zhu, Ling Pan, Yunfan Yang, Xingxia Zhang, Hongguo Zhao, Hairong Fei, Yonghuai Feng, Linhua Yang, Xiaoyi Lv, Hai Yi, Yilan Liu, Yun Zeng, Hua Fan, Liling Zheng, Jianmin Luo, Jianhui Qiao, Luoming Hua, Shasha Zhao, Yin Sai, Ronghua Hu, Lianyu Shen, Li Ding, Fang Ye, Shunjie Wu, Min Ouyang, Meixiang Zhao, Qin Li, Liru Wang, Wangxiang Huang, Wenqian Li, Jianli Wang, Yun Li, Jing Liu. QJ acknowledges support from the National Natural Science Foundation of China (No. 81970140). RPG acknowledges support from the National Institute of Health Research (NIHR) Biomedical Research Centre funding scheme.

Funding

Funded, in part, by the National Natural Science Foundation of China (No. 81970140) and CAMS Innovation Fund for Medical Sciences (CIFMS) (No. 2019-I2M-5-034).

Author information

Author notes

  1. These authors contributed equally: Feiyang Qi, Xiaoshuai Zhang, Robert Peter Gale, Bingcheng Liu, Jian Huang.

Authors and Affiliations

  1. Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China

    Feiyang Qi, Xiaoshuai Zhang, Xiaojun Huang & Qian Jiang

  2. Centre for Hematology, Department of Immunology and Inflammation, Imperial College of Science, Technology and Medicine, London, UK

    Robert Peter Gale

  3. National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

    Bingcheng Liu

  4. Department of Hematology, The First Affiliated Hospital of Zhejiang University, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

    Jian Huang

  5. Department of Hematology, The Fourth Affiliated Hospital of Zhejiang University, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

    Jian Huang

  6. Zhejiang Provincial Clinical Research Center for Haematological Disorders, Hangzhou, Zhejiang, China

    Jian Huang

  7. Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China

    Xiaojun Huang & Qian Jiang

  8. Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, 100044, China

    Xiaojun Huang

  9. Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Chinese Academy of Medical Sciences, 2019RU029, Beijing, 100044, China

    Xiaojun Huang

Authors
  1. Feiyang Qi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiaoshuai Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert Peter Gale
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bingcheng Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jian Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xiaojun Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Qian Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

QJ designed the study. QJ, FQ, XZ, BL, JH, and RPG analysed the data. QJ, XH, FQ, XZ, BL, JH, and RPG prepared the typescript. QJ, XH, BL, and JH provided the most part of patients’ data in this study. All authors approved the final typescript, take responsibility for the content and agree to submit for publication.

Corresponding authors

Correspondence to Xiaojun Huang or Qian Jiang.

Ethics declarations

Competing interests

RPG is a consultant to NexImmune Inc. and Ananexa Pharma Ascentage Pharm Group, Antengene Biotech LLC, Medical Director, FFF Enterprises Inc.; partner, AZAC Inc.; Board of Directors, Russian Foundation for Cancer Research Support; and Scientific Advisory Board: StemRad Ltd.

Ethical approval

Approved by the Ethics Committee of People’s Hospital Beijing compliant with principles of the Helsinki Declaration. Requirement for written informed consent was waived.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplement Table 1. Co-variates at diagnosis.

Supplement Table 2. Multi-variable analyses of cumulative incidences of MMR and MR4.

41375_2023_1982_MOESM3_ESM.docx

Supplement Figure 1. Time-dependent AUROC, Calibration plots, and Decision curve analyses of the MMR and MR4 predictive scoring systems.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Qi, F., Zhang, X., Gale, R.P. et al. External validation of the predictive scoring systems for molecular responses in chronic myeloid leukaemia receiving initial imatinib-therapy. Leukemia 37, 1922–1924 (2023). https://doi.org/10.1038/s41375-023-01982-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-023-01982-1

Search

Advanced search

Quick links